Business Context and Reporting Period
Company: Penumbra, Inc. (PEN)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Penumbra is a leading medical device company focused on thrombectomy (removing blood clots) and embolization/access technologies. The company operates as a single segment, selling primarily to healthcare providers in the U.S. and internationally.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | $1,403.7 million | $1,194.6 million | $1,058.5 million |
| Gross Profit | $942.4 million | $755.0 million | $682.6 million |
| Gross Margin | 67.1% | 63.2% | 64.5% |
| Operating Income | $189.2 million | $9.3 million | $73.6 million |
| Net Income | $177.7 million | $14.0 million | $91.0 million |
| Diluted EPS | $4.52 | $0.36 | $2.32 |
| Operating Cash Flow | $238.7 million | $168.5 million | $97.3 million |
| Cash & Marketable Investments | $544.8 million | $340.1 million | N/A |
| Working Capital | $1,033.6 million | $792.8 million | N/A |
Note: 2024 results were significantly impacted by a $115.3 million impairment and exit charge related to the immersive healthcare business.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 17.5% year-over-year, driven by 16.2% growth in Thrombectomy products and 20.2% growth in Embolization and Access products. U.S. sales grew 21.0%, while international sales grew 6.6%.
- Profitability Surge: Operating income jumped from $9.3 million in 2024 to $189.2 million in 2025. This improvement is largely due to the absence of the $115.3 million one-time impairment charge recorded in 2024 for the exit of the immersive healthcare business.
- Margin Expansion: Gross margin improved by 3.9 percentage points to 67.1%, aided by favorable product mix, productivity improvements, and the exclusion of the 2024 inventory write-down.
- Expense Management: R&D expenses decreased 5.3% to $89.8 million, primarily due to the cessation of immersive healthcare R&D costs. SG&A expenses increased 15.6% to $663.4 million, driven by headcount growth and marketing investments.
Guidance, Outlook, and Material Events
Proposed Merger with Boston Scientific
On January 14, 2026, Penumbra entered into a definitive agreement to be acquired by Boston Scientific Corporation. Key terms include:
- Enterprise Value: Approximately $14.5 billion.
- Consideration: $374 per share, with stockholders electing to receive either 100% cash or a mix of approximately 73% cash and 27% Boston Scientific stock.
- Timeline: Expected to close by the end of 2026, subject to regulatory and shareholder approvals.
- Termination Fees: Penumbra may be required to pay a $525 million termination fee under certain circumstances; Boston Scientific may be required to pay $900 million under others.
Risks and Contingencies
- Merger Uncertainty: Risks include failure to obtain regulatory approvals, shareholder rejection, or litigation that could delay or terminate the transaction.
- Supply Chain & Manufacturing: The company is constructing a new manufacturing facility in Costa Rica (expected completion 2026) to support growth. Dependence on single-source suppliers and sterilization capacity remains a risk.
- Regulatory Environment: Subject to stringent FDA and EU MDR regulations. Changes in reimbursement policies or pricing pressures could impact future margins.
Investor Verification Checklist
- Merger Approval Status: Monitor progress on regulatory clearances (FTC, EU) and shareholder vote results for the Boston Scientific acquisition.
- Merger Consideration Mix: Verify the final proration of cash vs. stock consideration, as the deal structure targets a 73/27 split but is subject to adjustment.
- Cost Synergies & Integration: Assess management's commentary on post-merger integration plans and potential cost synergies with Boston Scientific.
- Costa Rica Facility: Track the timeline and capital expenditure progress for the new Costa Rica manufacturing site to ensure it meets demand projections.
- Reimbursement Trends: Review updates on Medicare Severity Diagnosis-Related Group (MS-DRG) rates and private payer coverage for thrombectomy procedures.